Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep841 | Pituitary and Neuroendocrinology | ECE2022

Descriptive study of the acromegaly disease activity according to ACRODAT® in a tertiary Hospital in Spain

Carlos Percovich Hualpa Juan , Anez Roberto , Centeno Rogelio Garci a , Fernandez Laura Gonzalez , Munoz Diego , Montenegro Alejandra Maricel Rivas , Fernandez Fernandez Elisa , Guerrero Crystal , Gonzalez Albarran Olga

Background: The goals of acromegaly treatment are to achieve long-term biochemical control, control tumor size and decrease the risk of developing systemic comorbidities. Moreover, from the patientÂ’s perspective, symptoms and QoL are critical parameters of disease control and should be assessed routinely. To aid in the global clinical management of acromegaly, a holistic clinical decision support tool, the Acromegaly Disease Activity Tool (ACRODAT®) was developed.</p...

ea0070aep654 | Pituitary and Neuroendocrinology | ECE2020

Our experience with lu-dotatate in patients with neuroendocrine tumors in a tertiary hospital

Munoz Diego , Carlos Percovich Hualpa Juan , Weber Bettina , Atencia Goñi José , González Fernández Laura , Miguélez González María , Brox Torrecilla Noemí , José Añez Ramos Roberto , Maricel Rivas Montenegro Alejandra , López Guerra Aurelio , Lucía Olmedilla Isishi Yoko , Ángeles Vélez Romero María , Ágreda García Javier , Picallo Pérez María , Monereo Megías Susana , García Centeno Rogelio

Introduction: Lutetium-177-DOTATATE (Lu177) is approved in patients with well-differentiated (G1 and G2) neuroendocrine tumors (NETs) positive to somatostatin receptors, progressive and unresectable or metastatic. Lu177 has been shown to increase progression-free survival and the quality of life of these patients.Material and Methods: Retrospective descriptive study of a series of 15 cases with NETs treated with Lu177. Demographic data, tumor characteris...